Drug Trial Radar · NCT07227870
L19IL2/TNF in Patients With Basal Cell Carcinoma
Last checked: Nov 19, 2026Latest source record: Jul 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
92
Planned (sponsor's estimate)
Start
Sep 2026
Primary completion
Feb 2031
Study completion Feb 2031
Sponsor
- Lead sponsor
- Philogen S.p.A.Industry
- Sponsor type
- Industry
- First posted
- Nov 13, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Open-label, single-arm, multicentre study in patients with locally advanced BCC amenable to intratumoral injection, who have progressed on or are intolerant to systemic therapy as determined by a local multidisciplinary tumor board. The primary objective of the study is to evaluate the activity of intratumoral L19IL2/L19TNF, while the secondary objective is to assess the safety and efficacy. The patients will receive multiple intratumoral administrations of combined L19IL2 and L19TNF to all injectable cutaneous and subcutaneous lesions once weekly for up to 4 weeks: for those who have a partial response or stable disease as their best response, a second 4-week course L19IL2/L19TNF of four weekly injections may be administered as per treating physician judgement. Patients will be followed for a maximum of 160 weeks after beginning of treatment.
Conditions
- Locally Advanced Basal Cell Carcinoma
Interventions
L19IL2/L19TNFDrug
intratumoral administrations
Primary outcomes
What the sponsor says the trial is designed to measure.
- Best Overall Response Rate (BORR)Time frame: From enrollment up to a maximum of 160 weeks after the start of treatment
Locations
18 sites in 5 countries. Site status is shown where the registry gives one.
H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc.
Tampa, Florida · Recruiting
Winship Cancer Institute, Emory University
Atlanta, Georgia · Recruiting
Memorial Sloan Kettering
New York, New York · Not yet recruiting
The Ohio State University Wexner Medical Center Clinical Laboratories
Columbus, Ohio · Not yet recruiting
The University of Texas MD Anderson Cancer Center
Houston, Texas · Recruiting
Universitaetsklinikum Augsburg
Augsburg, Germany · Recruiting
Charite Universitaetsmedizin Berlin KöR
Berlin, Germany · Recruiting
Universitaetsklinikum Essen AöR
Essen, Germany · Recruiting
Universitaetsklinikum Halle (Saale) AöR
Halle, Germany · Recruiting
Heidelberg University
Heidelberg, Germany · Recruiting
Universitaetsklinikum Schleswig-Holstein AöR
Kiel, Germany · Recruiting
Universitaetsklinikum Tuebingen AöR
Tübingen, Germany · Recruiting
Andreas Syngros Hospital Of Venereal And Dermatological Diseases
Athens, Greece · Not yet recruiting
IRCCS Istituto Nazionale Tumori Fondazione Pascale
Naples, Italy · Recruiting
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Roma, Italy · Recruiting
Humanitas Mirasole S.p.A.
Rozzano, Italy · Recruiting
Azienda Ospedaliero-Universitaria Senese
Siena, Italy · Recruiting
Hospital Clinic De Barcelona
Barcelona, Spain · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.